Sanofi is making its largest investment in China to date, committing over $1 billion to build a state-of-the-art insulin manufacturing facility in Beijing. This marks the company’s fourth insulin plant in China, reflecting the rising demand for diabetes treatments among the country’s 140 million adults living with the disease.
Sanofi plans to integrate advanced automation, digital management systems, and sustainability practices into the new facility.
Disclaimer
Blogs and publications on this website are independent of any involvement by medtech companies or diabetes related charities. To ensure there is no bias, we do not accept any products, freebies or other material from any medtech provider. Except where credited otherwise, all materials are copyright ©️Love My Libre Ltd.
Love My Libre is not associated or affiliated with Abbott or FreeStyle Libre. Content here and on our website www.lovemylibre.com does not constitute medical advice or replace the relationship between you and healthcare professionals nor the advice you receive from them.
The author of this blog has type 1 diabetes and uses the FreeStyle Libre 2 which is provided on NHS prescription.
Leave a comment (all fields required). Please note, we are unable to respond to individual comments posted here.